[{"id":"88697519-a0e5-4dd6-90f5-d7ce8a3d445d","acronym":"RAPID","url":"https://clinicaltrials.gov/study/NCT00268853","created_at":"2021-07-05T15:58:28.279Z","updated_at":"2024-07-02T16:35:00.098Z","phase":"Phase 2","brief_title":"A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin","source_id_and_acronym":"NCT00268853 - RAPID","lead_sponsor":"CTI BioPharma","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Pixuvri (pixantrone)"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 11/01/2005","start_date":" 11/01/2005","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2024-05-30"},{"id":"67fedc8a-9740-4fad-9927-14a7a20342ff","acronym":"PIVeR","url":"https://clinicaltrials.gov/study/NCT03458260","created_at":"2021-01-18T17:02:56.639Z","updated_at":"2024-07-02T16:35:35.779Z","phase":"Phase 2","brief_title":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03458260 - PIVeR","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Pixuvri (pixantrone)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 06/15/2019","primary_completion_date":" 06/15/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-26"},{"id":"d480f6a7-cf34-464a-8e5a-314c5f26cb4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00551239","created_at":"2021-01-18T02:00:27.523Z","updated_at":"2024-07-02T16:36:39.953Z","phase":"Phase 3","brief_title":"Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00551239","lead_sponsor":"CTI BioPharma","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • fludarabine IV • Pixuvri (pixantrone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2007","start_date":" 08/01/2007","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-10-19"},{"id":"d308ccc6-0a04-432f-a57f-9f2bd5d279c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00577161","created_at":"2021-01-18T02:06:39.471Z","updated_at":"2024-07-02T16:36:40.401Z","phase":"Phase 3","brief_title":"Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL","source_id_and_acronym":"NCT00577161","lead_sponsor":"CTI BioPharma","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • fludarabine IV • Pixuvri (pixantrone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 07/01/2012","study_completion_date":" 07/01/2012","last_update_posted":"2020-10-05"}]